228 related articles for article (PubMed ID: 26540491)
1. Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial.
Wise R; Calverley PM; Dahl R; Dusser D; Metzdorf N; Müller A; Fowler A; Anzueto A
NPJ Prim Care Respir Med; 2015 Nov; 25():15067. PubMed ID: 26540491
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial.
Dahl R; Calverley PM; Anzueto A; Metzdorf N; Fowler A; Mueller A; Wise R; Dusser D
BMJ Open; 2015 Dec; 5(12):e009015. PubMed ID: 26715479
[TBL] [Abstract][Full Text] [Related]
3. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R
Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563
[TBL] [Abstract][Full Text] [Related]
4. TIOtropium Safety and Performance In Respimat
Zhong N; Moon HS; Lee KH; Mahayiddin AA; Boonsawat W; Isidro MG; Bai C; Mueller A; Metzdorf N; Anzueto A
Respirology; 2016 Nov; 21(8):1397-1403. PubMed ID: 27490162
[TBL] [Abstract][Full Text] [Related]
5. Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR
Wise RA; Calverley PM; Carter K; Clerisme-Beaty E; Metzdorf N; Anzueto A
Int J Chron Obstruct Pulmon Dis; 2018; 13():605-616. PubMed ID: 29497289
[TBL] [Abstract][Full Text] [Related]
6. Tiotropium Respimat inhaler and the risk of death in COPD.
Wise RA; Anzueto A; Cotton D; Dahl R; Devins T; Disse B; Dusser D; Joseph E; Kattenbeck S; Koenen-Bergmann M; Pledger G; Calverley P;
N Engl J Med; 2013 Oct; 369(16):1491-501. PubMed ID: 23992515
[TBL] [Abstract][Full Text] [Related]
7. Tiotropium Respimat(®) vs. HandiHaler(®): real-life usage and TIOSPIR trial generalizability.
Schmiedl S; Fischer R; Ibanez L; Fortuny J; Thürmann P; Ballarin E; Ferrer P; Sabaté M; Rottenkolber D; Gerlach R; Tauscher M; Reynolds R; Hasford J; Rottenkolber M
Br J Clin Pharmacol; 2016 Feb; 81(2):379-88. PubMed ID: 26506314
[TBL] [Abstract][Full Text] [Related]
8. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.
Halpin DM; Dahl R; Hallmann C; Mueller A; Tashkin D
Int J Chron Obstruct Pulmon Dis; 2015; 10():239-59. PubMed ID: 25709423
[TBL] [Abstract][Full Text] [Related]
9. The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale.
Wise RA; Anzueto A; Calverley P; Dahl R; Dusser D; Pledger G; Koenen-Bergmann M; Joseph E; Cotton D; Disse B
Respir Res; 2013 Apr; 14(1):40. PubMed ID: 23547660
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
ZuWallack R; Allen L; Hernandez G; Ting N; Abrahams R
Int J Chron Obstruct Pulmon Dis; 2014; 9():1133-44. PubMed ID: 25342898
[TBL] [Abstract][Full Text] [Related]
11. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
[TBL] [Abstract][Full Text] [Related]
12. Demographic Characteristics and Clinical Outcomes in Patients from Latin America Versus the Rest of the World: A TIOSPIR
Anzueto A; Calverley PMA; Mueller A; Metzdorf N; Haensel M; Jardim JR; Pizzichini E; Giraldo H; Ramirez-Venegas A; Giugno ER
Arch Bronconeumol (Engl Ed); 2018 Mar; 54(3):140-148. PubMed ID: 29317111
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?
Dahl R; Kaplan A
BMC Pulm Med; 2016 Oct; 16(1):135. PubMed ID: 27724909
[TBL] [Abstract][Full Text] [Related]
14. Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch.
Hanada S; Wada S; Ohno T; Sawaguchi H; Muraki M; Tohda Y
Int J Chron Obstruct Pulmon Dis; 2015; 10():69-77. PubMed ID: 25609941
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C
Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642
[TBL] [Abstract][Full Text] [Related]
16. Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials.
Cooper CB; Anzueto A; Decramer M; Celli B; Tashkin DP; Leimer I; Kesten S
Int J Chron Obstruct Pulmon Dis; 2011; 6():269-75. PubMed ID: 21845038
[TBL] [Abstract][Full Text] [Related]
17. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices.
Asakura Y; Nishimura N; Maezawa K; Terajima T; Kizu J; Chohnabayashi N
J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112
[TBL] [Abstract][Full Text] [Related]
18. Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: are they equivalent?
Mathioudakis AG; Chatzimavridou-Grigoriadou V; Evangelopoulou E; Mathioudakis GA; Siafakas NM
Pulm Pharmacol Ther; 2014 Aug; 28(2):91-7. PubMed ID: 24846455
[TBL] [Abstract][Full Text] [Related]
19. Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair
Yildiz P; Bayraktaroglu M; Gorgun D; Secik F
Int J Chron Obstruct Pulmon Dis; 2016; 11():2859-2867. PubMed ID: 27920513
[TBL] [Abstract][Full Text] [Related]
20. Tiotropium versus placebo for chronic obstructive pulmonary disease.
Karner C; Chong J; Poole P
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD009285. PubMed ID: 25046211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
